Mustafa H Syed

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6587328/publications.pdf

Version: 2024-02-01

1478505 1872680 2,763 9 6 6 citations h-index g-index papers 9 9 9 7723 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Evaluation of a Combined Multilocus Sequence Typing and Whole-Genome Sequencing Two-Step Algorithm for Routine Typing of <i>Clostridioides difficile</i> . Journal of Clinical Microbiology, 2021, 59, .	3.9	8
2	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. Journal of Molecular Diagnostics, 2021, 23, 181-199.	2.8	19
3	Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications. Leukemia and Lymphoma, 2020, 61, 460-464.	1.3	0
4	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nature Medicine, 2020, 26, 1742-1753.	30.7	185
5	Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. Blood Cancer Journal, 2020, 10, 76.	6.2	9
6	Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms. Journal of Molecular Diagnostics, 2019, 21, 330-342.	2.8	69
7	Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a "Spike-in" Clonal Sequence. Blood, 2019, 134, 3380-3380.	1.4	O
8	Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection. Blood, 2018, 132, 4475-4475.	1.4	0
9	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473